SURVEILLANCE OF ANTIFUNGAL PRACTICES AMONG PEDIATRIC HEMATOLOGY-ONCOLOGY PHYSICIANS (ESPID 2026) - May 28, 2026 - Abstract #EPV-0064; Pres time: Jun 1, 2026; 07:00 AM - 07:00 PM; Location: E-Poster Area; "Antifungal prophylaxis was routinely implemented by 23/26 respondents (88.5%), using fluconazole (20/26, 76.9%), followed by echinocandins (4/26, 15.4%) and liposomal amphotericin B (2/26, 7.7%), primarily in patients with severe neutropenia or other risks. Therapeutic drug monitoring was available to 5/26 respondents (19.2%), whereas newer antifungal agents, including isavuconazole and novel posaconazole formulation, were accessible to 24/26 respondents (92.3%)...Conclusions/Learning Points Variability in the diagnosis and management of IFI exists in Pediatric Oncology units in Greece. Structured surveillance programs and optimized antifungal stewardship are necessary tools to improve patient outcomes."
Clinical • Infectious Disease
|
|
Kravari Z. 1; Iosifidis E. 1; Roilides E. 1; Kourti M. 2
|